- Investing Ideas
- /
- U.S. Undervalued Stocks Based On Cash Flows
U.S. Undervalued Stocks Based On Cash Flows
UPDATED May 12, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
439 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
ARBB | US$0.94 | -14.1% | -76.6% | US$25.0m | US$3.00 | PB1.2x | E139.1% | n/a | Software | ||
PPSI | US$3.99 | 3.9% | -26.1% | US$39.6m | US$10.50 | PE22.3x | E37.6% | n/a | Capital Goods | ||
AUNA | US$9.48 | 41.1% | n/a | US$700.7m | US$16.05 | PB1.8x | E45.4% | n/a | Healthcare | ||
ECOR | US$6.84 | -2.3% | 2.2% | US$41.1m | US$23.16 | PS1.9x | E63.9% | n/a | Healthcare | ||
YSG | US$4.54 | 4.1% | -1.4% | US$486.9m | US$4.35 | PS1x | E120.5% | n/a | Household | ||
OPNT | US$20.65 | -1.3% | -22.3% | US$108.8m | US$21.50 | PS4.9x | E62.6% | n/a | Pharmaceuticals & Biotech | ||
AXSM | US$72.50 | -4.5% | -6.8% | US$3.4b | US$123.56 | PS13.7x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$205.25 | -12.9% | -29.3% | US$4.4b | US$363.86 | PB5.1x | E65.1% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.77 | -8.5% | -63.1% | US$224.0m | US$9.25 | PB2x | E61.1% | n/a | Pharmaceuticals & Biotech | ||
HRMY | US$30.14 | -2.5% | -17.5% | US$1.7b | US$42.25 | PE12.4x | E28.4% | n/a | Pharmaceuticals & Biotech | ||
VRME | US$1.76 | 0% | 11.4% | US$17.9m | US$2.85 | PB1.4x | E70.2% | n/a | Tech | ||
COMP | US$3.90 | 16.1% | 0.8% | US$1.9b | US$4.07 | PB5.8x | E85.8% | n/a | Real Estate Management and Development | ||
ASLE | US$7.96 | 6.1% | -49.6% | US$422.0m | US$10.50 | PE595.1x | E117.6% | n/a | Capital Goods | ||
SLNO | US$44.99 | -2.1% | 969.9% | US$1.6b | US$68.17 | PB11.4x | E64.2% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$7.77 | -15.1% | 74.2% | US$1.8b | US$13.83 | PS11.4x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
IMAX | US$16.63 | -2.5% | -14.0% | US$875.2m | US$22.25 | PE33.5x | E27.3% | n/a | Media | ||
EOLS | US$12.75 | -4.8% | 23.5% | US$798.3m | US$22.29 | PS3.6x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
PCRX | US$29.42 | 11.0% | -30.7% | US$1.4b | US$44.90 | PE19.4x | E29.9% | n/a | Pharmaceuticals & Biotech | ||
TTI | US$4.02 | 4.1% | 45.1% | US$527.2m | US$7.42 | PE25.9x | E43.3% | n/a | Energy | ||
INFN | US$5.06 | -4.5% | 2.6% | US$1.2b | US$7.27 | PB6.5x | E138.9% | n/a | Tech | ||
WULF | US$2.23 | -7.9% | 41.1% | US$674.0m | US$3.62 | PS9.7x | E132.9% | n/a | Software | ||
ITCI | US$64.96 | -8.5% | 0.08% | US$6.9b | US$90.60 | PS13.3x | E61.0% | n/a | Pharmaceuticals & Biotech | ||
IRWD | US$7.00 | -13.7% | -33.5% | US$1.1b | US$16.33 | PS2.7x | E70.3% | n/a | Pharmaceuticals & Biotech | ||
GAME | US$1.46 | 6.2% | -65.0% | US$44.1m | US$5.00 | PB2.4x | E100.9% | n/a | Media |